Antibody‐guided diagnosis

An italian experience on cea‐expressing tumours

Pietro Riva, G. Moscatelli, G. Paganelli, S. Benini, Antonio Siccardi

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Within the Italian CNR Biomedcal Technology programmes a large multicentre clinical trial on CEA‐expressing carcinomas has been carried out. F(ab')2 fragments of anti‐CEA monoclonal antibody (MAb) FO23C5, radiolabelled with either 131l or III In, were supplied to 10 different Italian nuclear medicine departments. Over 500 patients with gastrointestinal, lung, breast, and other carcinomas have been investigated. The results obtained in our nuclear medicine department are reported here. In GI cancer group, the 131I compound showed better results except in liver metastases detected only in 28/57 patients. In the lung cancer group, very satisfactory results were achieved in primary tumours and local or systemic recurrences: III In tracer was preferentially used. In the breast cancer group immunoscintigraphy proved to be helpful in differential diagnosis of neoplastic and benign bone lesions. Significant improvements of diagnostic sensitivity were achieved in GI cancer patients by means of i.p. administration. Finally, 12 patients with advanced disease were given different 131l radioiodnated MAbs (100 mCi average dose). Administration route was either i.v. (3 cases) or i.p. (9 cases). Clinical and instrumental evidence of complete (I) or partial (7) response was observed in 8 patients.

Original languageEnglish
Pages (from-to)114-120
Number of pages7
JournalInternational Journal of Cancer
Volume41
Issue number2 S
DOIs
Publication statusPublished - 1988

Fingerprint

Nuclear Medicine
Neoplasms
Breast Neoplasms
Multicenter Studies
Lung Neoplasms
Differential Diagnosis
Clinical Trials
Neoplasm Metastasis
Technology
Carcinoma
Bone and Bones
Recurrence
Lung
Liver
FO23C5 monoclonal antibody

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Antibody‐guided diagnosis : An italian experience on cea‐expressing tumours. / Riva, Pietro; Moscatelli, G.; Paganelli, G.; Benini, S.; Siccardi, Antonio.

In: International Journal of Cancer, Vol. 41, No. 2 S, 1988, p. 114-120.

Research output: Contribution to journalArticle

Riva, Pietro ; Moscatelli, G. ; Paganelli, G. ; Benini, S. ; Siccardi, Antonio. / Antibody‐guided diagnosis : An italian experience on cea‐expressing tumours. In: International Journal of Cancer. 1988 ; Vol. 41, No. 2 S. pp. 114-120.
@article{7214fdb03b364516bcf152956eee11b9,
title = "Antibody‐guided diagnosis: An italian experience on cea‐expressing tumours",
abstract = "Within the Italian CNR Biomedcal Technology programmes a large multicentre clinical trial on CEA‐expressing carcinomas has been carried out. F(ab')2 fragments of anti‐CEA monoclonal antibody (MAb) FO23C5, radiolabelled with either 131l or III In, were supplied to 10 different Italian nuclear medicine departments. Over 500 patients with gastrointestinal, lung, breast, and other carcinomas have been investigated. The results obtained in our nuclear medicine department are reported here. In GI cancer group, the 131I compound showed better results except in liver metastases detected only in 28/57 patients. In the lung cancer group, very satisfactory results were achieved in primary tumours and local or systemic recurrences: III In tracer was preferentially used. In the breast cancer group immunoscintigraphy proved to be helpful in differential diagnosis of neoplastic and benign bone lesions. Significant improvements of diagnostic sensitivity were achieved in GI cancer patients by means of i.p. administration. Finally, 12 patients with advanced disease were given different 131l radioiodnated MAbs (100 mCi average dose). Administration route was either i.v. (3 cases) or i.p. (9 cases). Clinical and instrumental evidence of complete (I) or partial (7) response was observed in 8 patients.",
author = "Pietro Riva and G. Moscatelli and G. Paganelli and S. Benini and Antonio Siccardi",
year = "1988",
doi = "10.1002/ijc.2910410726",
language = "English",
volume = "41",
pages = "114--120",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "2 S",

}

TY - JOUR

T1 - Antibody‐guided diagnosis

T2 - An italian experience on cea‐expressing tumours

AU - Riva, Pietro

AU - Moscatelli, G.

AU - Paganelli, G.

AU - Benini, S.

AU - Siccardi, Antonio

PY - 1988

Y1 - 1988

N2 - Within the Italian CNR Biomedcal Technology programmes a large multicentre clinical trial on CEA‐expressing carcinomas has been carried out. F(ab')2 fragments of anti‐CEA monoclonal antibody (MAb) FO23C5, radiolabelled with either 131l or III In, were supplied to 10 different Italian nuclear medicine departments. Over 500 patients with gastrointestinal, lung, breast, and other carcinomas have been investigated. The results obtained in our nuclear medicine department are reported here. In GI cancer group, the 131I compound showed better results except in liver metastases detected only in 28/57 patients. In the lung cancer group, very satisfactory results were achieved in primary tumours and local or systemic recurrences: III In tracer was preferentially used. In the breast cancer group immunoscintigraphy proved to be helpful in differential diagnosis of neoplastic and benign bone lesions. Significant improvements of diagnostic sensitivity were achieved in GI cancer patients by means of i.p. administration. Finally, 12 patients with advanced disease were given different 131l radioiodnated MAbs (100 mCi average dose). Administration route was either i.v. (3 cases) or i.p. (9 cases). Clinical and instrumental evidence of complete (I) or partial (7) response was observed in 8 patients.

AB - Within the Italian CNR Biomedcal Technology programmes a large multicentre clinical trial on CEA‐expressing carcinomas has been carried out. F(ab')2 fragments of anti‐CEA monoclonal antibody (MAb) FO23C5, radiolabelled with either 131l or III In, were supplied to 10 different Italian nuclear medicine departments. Over 500 patients with gastrointestinal, lung, breast, and other carcinomas have been investigated. The results obtained in our nuclear medicine department are reported here. In GI cancer group, the 131I compound showed better results except in liver metastases detected only in 28/57 patients. In the lung cancer group, very satisfactory results were achieved in primary tumours and local or systemic recurrences: III In tracer was preferentially used. In the breast cancer group immunoscintigraphy proved to be helpful in differential diagnosis of neoplastic and benign bone lesions. Significant improvements of diagnostic sensitivity were achieved in GI cancer patients by means of i.p. administration. Finally, 12 patients with advanced disease were given different 131l radioiodnated MAbs (100 mCi average dose). Administration route was either i.v. (3 cases) or i.p. (9 cases). Clinical and instrumental evidence of complete (I) or partial (7) response was observed in 8 patients.

UR - http://www.scopus.com/inward/record.url?scp=84987453881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987453881&partnerID=8YFLogxK

U2 - 10.1002/ijc.2910410726

DO - 10.1002/ijc.2910410726

M3 - Article

VL - 41

SP - 114

EP - 120

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 2 S

ER -